340 related articles for article (PubMed ID: 17255159)
21. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
Mabjeesh NJ; Chen J; Stenger A; Matzkin H
Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
[TBL] [Abstract][Full Text] [Related]
22. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
[TBL] [Abstract][Full Text] [Related]
23. Rectal toxicity profile after transperineal interstitial permanent prostate brachytherapy: use of a comprehensive toxicity scoring system and identification of rectal dosimetric toxicity predictors.
Shah JN; Ennis RD
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):817-24. PubMed ID: 16297567
[TBL] [Abstract][Full Text] [Related]
24. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
[TBL] [Abstract][Full Text] [Related]
25. Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose-volume effect.
Zapatero A; García-Vicente F; Modolell I; Alcántara P; Floriano A; Cruz-Conde A; Torres JJ; Pérez-Torrubia A
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1343-51. PubMed ID: 15275719
[TBL] [Abstract][Full Text] [Related]
26. Favorable toxicity and biochemical control using real-time inverse optimization technique for prostate brachytherapy.
Raben A; Rusthoven KE; Sarkar A; Glick A; Benge B; Jacobs D; Raben D
Brachytherapy; 2009; 8(3):297-303. PubMed ID: 19213608
[TBL] [Abstract][Full Text] [Related]
27. [Acute adverse effects of high dose brachytherapy in combination with external radiotherapy in localized prostate cancer].
Soumarová R; Homola L; Stursa M; Perková H
Cas Lek Cesk; 2006; 145(1):43-9. PubMed ID: 16468241
[TBL] [Abstract][Full Text] [Related]
28. Dose-volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probability.
D'Souza WD; Thames HD; Kuban DA
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1540-8. PubMed ID: 15050335
[TBL] [Abstract][Full Text] [Related]
29. A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy.
Cesaretti JA; Stock RG; Atencio DP; Peters SA; Peters CA; Burri RJ; Stone NN; Rosenstein BS
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1410-6. PubMed ID: 17490827
[TBL] [Abstract][Full Text] [Related]
30. [Brachytherapy for prostate carcinoma].
Yorozu A
Nihon Igaku Hoshasen Gakkai Zasshi; 2005 Apr; 65(2):87-91. PubMed ID: 15920966
[TBL] [Abstract][Full Text] [Related]
31. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.
Lee HK; Adams MT; Motta J
Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939
[TBL] [Abstract][Full Text] [Related]
32. Dosimetry and cancer control after low-dose-rate prostate brachytherapy.
Robert Lee W; Deguzman AF; McMullen KP; McCullough DL
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):52-9. PubMed ID: 15629593
[TBL] [Abstract][Full Text] [Related]
33. Brachytherapy for prostate cancer: summary of American Brachytherapy Society recommendations.
Nag S
Semin Urol Oncol; 2000 May; 18(2):133-6. PubMed ID: 10875454
[TBL] [Abstract][Full Text] [Related]
34. Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications.
Zelefsky MJ; Yamada Y; Cohen GN; Sharma N; Shippy AM; Fridman D; Zaider M
Radiother Oncol; 2007 Aug; 84(2):185-9. PubMed ID: 17692978
[TBL] [Abstract][Full Text] [Related]
35. High-dose-rate interstitial brachytherapy for gynecologic malignancies.
Beriwal S; Bhatnagar A; Heron DE; Selvaraj R; Mogus R; Kim H; Gerszten K; Kelley J; Edwards RP
Brachytherapy; 2006; 5(4):218-22. PubMed ID: 17118313
[TBL] [Abstract][Full Text] [Related]
36. Novel prostate brachytherapy technique: improved dosimetric and clinical outcome.
Nobes JP; Khaksar SJ; Hawkins MA; Cunningham MJ; Langley SE; Laing RW
Radiother Oncol; 2008 Jul; 88(1):121-6. PubMed ID: 18499289
[TBL] [Abstract][Full Text] [Related]
37. Low morbidity following high dose rate brachytherapy in the setting of prior transurethral prostate resection.
Peddada AV; Jennings SB; Faricy PO; Walsh RA; White GA; Monroe AT
J Urol; 2007 Nov; 178(5):1963-7. PubMed ID: 17868718
[TBL] [Abstract][Full Text] [Related]
38. High-dose-rate brachytherapy plus external beam radiotherapy for T1 to T3 prostate cancer: an experience in Taiwan.
Chen YC; Chuang CK; Hsieh ML; Chen WC; Fan KH; Yeh CY; Lee CC; Hong JH
Urology; 2007 Jul; 70(1):101-5. PubMed ID: 17656217
[TBL] [Abstract][Full Text] [Related]
39. Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer.
Zaider M; Zelefsky MJ; Cohen GN; Chui CS; Yorke ED; Ben-Porat L; Happersett L
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):702-13. PubMed ID: 15708248
[TBL] [Abstract][Full Text] [Related]
40. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy.
Kollmeier MA; Stock RG; Cesaretti J; Stone NN
J Urol; 2005 Mar; 173(3):808-12. PubMed ID: 15711274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
